Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

a large cross-sectional study

Josef S. Smolen*, Dafna Gladman, H. Patrick McNeil, Philip J. Mease, Joachim Sieper, Maja Hojnik, Pascal Nurwakagari, John Weinman

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Citations (Scopus)
8 Downloads (Pure)

Abstract

Objective This analysis explored the association of treatment adherence with beliefs about medication, patient demographic and disease characteristics and medication types in rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) to develop adherence prediction models. Methods The population was a subset from ALIGN, a multicountry, cross-sectional, self-administered survey study in adult patients (n=7328) with six immune-mediated inflammatory diseases who were routinely receiving systemic therapy. Instruments included Beliefs about Medicines Questionnaire (BMQ) and 4-item Morisky Medication Adherence Scale (MMAS-4©), which was used to define adherence. Results A total of 3390 rheumatological patients were analysed (RA, n=1943; PsA, n=635; AS, n=812). Based on the strongest significant associations, the adherence prediction models included type of treatment, age, race (RA and AS) or disease duration (PsA) and medication beliefs (RA and PsA, BMQ-General Harm score; AS, BMQ-Specific Concerns score). The models had cross-validated areas under the receiver operating characteristic curve of 0.637 (RA), 0.641 (PsA) and 0.724 (AS). Predicted probabilities of full adherence (MMAS-4©=4) ranged from 5% to 96%. Adherence was highest for tumour necrosis factor inhibitors versus other treatments, older patients and those with low treatment harm beliefs or concerns. Adherence was higher in white patients with RA and AS and in patients with PsA with duration of disease <9 years. Conclusions For the first time, simple medication adherence prediction models for patients with RA, PsA and AS are available, which may help identify patients at high risk of non-adherence to systemic therapies. Trial registration number ACTRN12612000977875.

Original languageEnglish
Article numbere000585
Pages (from-to)1-13
Number of pages13
JournalRMD Open
Volume5
Issue number1
DOIs
Publication statusPublished - Feb 2019

Bibliographical note

Copyright the Author(s) 2019. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • adherence
  • ankylosing spondylitis
  • disease-modifying antirheumatic drugs
  • psoriatic arthritis
  • rheumatoid arthritis

Fingerprint Dive into the research topics of 'Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study'. Together they form a unique fingerprint.

  • Cite this